Tag Archives: Roundup

Weekly Roundup for AUGUST 16, 2019: Recent Publications in Women’s Mental Health

Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Zheng W, Cai DB, Zheng W, Sim K, Ungvari GS, Peng XJ, Ning YP, Wang G, Xiang YT.  Psychiatry Res. 2019 Jul 4;279:83-89.  A single brexanolone infusion appears to have ultra-rapid antidepressant effect for PPD, lasting for up to 1 week.  GABAAR Modulator for Postpartum… Read More »

Research Roundup: Surprise Bills, ACOs and Mental Health Care

Each week, KHN compiles a selection of recently released health policy studies and briefs. JAMA Internal Medicine: Assessment Of Out-Of-Network Billing For Privately Insured Patients Receiving Care In In-Network Hospitals  Although surprise medical bills are receiving considerable attention from lawmakers and the news media, to date there has been little systematic study of the incidence… Read More »

Bayer’s already in the hot seat with investors. A new $2B Roundup slapdown won’t help

With angry investors at the gates and thousands of lawsuits tied up in court, Bayer’s executives have scrambled to keep their head above water. Looks like relief isn’t coming any time soon, at least not in the courtroom. A California jury hit Bayer, which now sells glyphosate-based weed killer Roundup, with $ 2 billion in… Read More »

Monsanto Argues Roundup Cancer Victim Should Receive Less Money Because of Imminent Death

August 10, 2018, a jury found Monsanto (now owned by Bayer AG1,2) had “acted with malice or oppression” and was responsible for “negligent failure” by not warning consumers about the carcinogenicity of its weed killer, Roundup.3,4 The plaintiff in this historic case was 46-year-old Dewayne Johnson, who is dying from Non-Hodgkin lymphoma. Johnson sprayed about… Read More »

Weekly Roundup for MARCH 22, 2019: Recent Publications in Women’s Mental Health

The excitement over the FDA approval of brexanolone (to be marketed as Zulresso) is a good place to start this week’s roundup.  Brexanolone is a derivative of the neurosteroid allopregnanolone, and, while Zulpresso was approved specifically for the treatment of postpartum depression, there is considerable research to indicate that the modulation of neurosteroid systems may… Read More »